famotidine NDC 62135-808

NDC codes

FDA NDC Directory

Product NDC (as listed)62135-808Labeler and product segments. Claims need a package NDC.

Product NDC at billing width62135-0808Add the package segment from the table below.

Package NDCs as listed with the FDA, and the 11-digit 5-4-2 form used on claims. The highlighted digit is the added leading zero.
Package NDC	11-digit (billing)	Package	Copy
62135-808-90	62135080890	90 TABLET, FILM COATED in 1 BOTTLE (62135-808-90)Marketed from Dec 8, 2023

How the 11-digit form is made: The product segment has 3 digits, so one leading zero is added to it (5-3-2 → 5-4-2). Formatting the NDC does not by itself make it billable — the product, package and quantity must match what was dispensed or administered, and payer rules apply. Conversion rules

Product information

Brand name (proprietary): famotidine
Generic name (nonproprietary): famotidine
Active ingredients: Famotidine — 40 mg/1
Dosage form: Tablet, Film coated
Route: Oral
Labeler: Chartwell RX, LLC
Product type: Prescription drug
Marketing category: ANDA — Abbreviated New Drug Application (generic)Application ANDA 075786
Marketing start: Sep 23, 2020
Listing expires: Dec 31, 2026
Other FDA classes: Histamine H2 Receptor Antagonists (Mechanism)
Identifiers: Product ID 62135-808_42c9eb63-96d0-3757-e063-6394a90ad58fSPL ID 42c9eb63-96d0-3757-e063-6394a90ad58fSPL set ID 70714491-1368-4824-98af-03fda52139a9RxCUI 284245, 310273UNII 5QZO15J2Z8UPC 0362135807900, 0362135808907
Pharmacologic class: Histamine-2 Receptor Antagonist

Billing references

What Med-Code can say about coding this product, and where each statement comes from. Nothing here is inferred from the name alone.

HCPCS codeNo match

No HCPCS code in Med-Code's directory. Oral products like this are usually dispensed by a pharmacy and billed by NDC.

NDC on a medical claim

N462135080890 followed by a unit qualifier and the quantity

Package 62135-0808-90. Unit qualifiers: F2 (international unit), GR (gram), ME (milligram), ML (milliliter), UN (unit (each)). The qualifier and quantity depend on what was given. About the N4 qualifier

Product label

Current FDA label (SPL), effective Nov 4, 2025.

Indications (excerpt from the label)

Famotidine tablets are indicated in adult and pediatric patients 40 kg and greater for the treatment of: active duodenal ulcer (DU). active gastric ulcer (GU). symptomatic nonerosive gastroesophageal reflux disease (GERD). erosive esophagitis due to GERD, diagnosed by biopsy. Famotidine tablets are indicated in adults for the: treatment of pathological hypersecretory conditions (e.g., Zollinger-Ellison syndrome, multiple endocrine neoplasias). reduction of the risk of duodenal ulcer recurrence. Famotidine tablets is a histamine-2 (H 2 ) receptor antagonist indicated ( 1) : In adult and pediatric patients 40 kg and greater for the treatment of: active duodenal ulcer (DU). active gastric ulcer…

Excerpt only. Read the full label for complete information.

Full label on DailyMed (opens in a new tab)

Other NDCs under ANDA 075786

Products listed under the same FDA application: other strengths and forms, and repackagers who relabel the same product.

FDA NDC Directory listings under ANDA 075786
Product	Strength	Form · route	Labeler	Product NDC
famotidine	Famotidine 20 mg/1	Tablet, Film coatedOral	Chartwell RX, LLC	62135-807